Valence Life Sciences
VC Fund
New York, United States
Valence Life Sciences is a VC fund in New York focused on Health Care and Biotechnology. Valence Life Sciences is the only life sciences venture firm with a proven track record of success in late-stage investing. Our team has insight on what drives success from assessing management and clinical development plans for over 25 years.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Valence Life Sciences invests in
Stages Valence Life Sciences invests in
Countries Valence Life Sciences invests in
Investment Focus
Industry
- Health Care 4 (50%)
- Biotechnology 2 (25%)
- Medical Device 2 (25%)
- Medical 1 (13%)
- Biopharma 1 (13%)
Stage
- Series D 2 (25%)
- Private Equity 2 (25%)
- Series C 1 (13%)
- Series E 1 (13%)
- Funding Round 1 (13%)
Country
- United States 3 (38%)
- Germany 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M / Series D / Mar 11, 2021 | |
|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $15M / Series C / May 22, 2020 | |
JenaValve Technology
|
JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M / Venture - Series Unknown / Feb 05, 2020 | |
Invuity
|
Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques.Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California. | $22.9M / Private Equity / Feb 13, 2015 | |
|
Invuity
|
Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques.Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California. | $36M / Series E / Mar 04, 2014 | |
Celator Pharmaceuticals
|
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351(Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey. | $39.3M / Private Equity / Apr 30, 2013 | |
|
Invuity
|
Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques.Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California. | $25M / Series D / Jun 14, 2012 | |
|
Invuity
|
Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques.Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California. | $2M / Jan 09, 2012 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Valence Life Sciences invest in?
Valence Life Sciences invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series D and Private Equity stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Valence Life Sciences last invest?
The most recent investment recorded for Valence Life Sciences closed in Mar 2021. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
